BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vuorio A, Kovanen PT. Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond. Front Pharmacol 2020;11:579548. [PMID: 33542685 DOI: 10.3389/fphar.2020.579548] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Kovanen PT, Raal F, Vuorio A. Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction. Am J Prev Cardiol 2021;7:100224. [PMID: 34312613 DOI: 10.1016/j.ajpc.2021.100224] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sathekge M, Byttebier G, De Spiegeleer B, Saxberg B, Ueckermann V, Belmans L, Alexander M, Fedson D. Adjunctive Use of Statins for COVID-19. J Clin Med 2021;10:1407. [PMID: 33915784 DOI: 10.3390/jcm10071407] [Reference Citation Analysis]
3 Vuorio A, Raal F, Kaste M, Kovanen PT. Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment. Atherosclerosis 2021;320:53-60. [PMID: 33540179 DOI: 10.1016/j.atherosclerosis.2021.01.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
4 Vuorio A, Strandberg TE, Raal F, Santos RD, Kovanen PT. Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition. Atheroscler Plus 2021;43:3-6. [PMID: 34622243 DOI: 10.1016/j.athplu.2021.08.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rasmi Y, Heidari N, Kübra Kırboğa K, Hatamkhani S, Tekin B, Alipour S, Naderi R, Farnamian Y, Akca I. The importance of neopterin in COVID-19: The prognostic value and relation with the disease severity. Clinical Biochemistry 2022. [DOI: 10.1016/j.clinbiochem.2022.03.002] [Reference Citation Analysis]
6 Vuorio A, Kaste M, Kovanen PT. Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke. eNeurologicalSci 2021;23:100344. [PMID: 33937536 DOI: 10.1016/j.ensci.2021.100344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Khanna AK, Khanna D. Venous Thromboembolism and COVID-19-an Epidemiological Perspective. Indian J Surg 2022;:1-8. [PMID: 35529246 DOI: 10.1007/s12262-022-03423-2] [Reference Citation Analysis]
8 Vuorio A, Lassila R, Kovanen PT. Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism. Front Cardiovasc Med 2021;8:711923. [PMID: 34722654 DOI: 10.3389/fcvm.2021.711923] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Proto MC, Fiore D, Piscopo C, Pagano C, Galgani M, Bruzzaniti S, Laezza C, Gazzerro P, Bifulco M. Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets. Prog Lipid Res 2021;82:101099. [PMID: 33915202 DOI: 10.1016/j.plipres.2021.101099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kouhpeikar H, Khosaravizade Tabasi H, Khazir Z, Naghipour A, Mohammadi Moghadam H, Forouzanfar H, Abbasifard M, Kirichenko TV, Reiner Ž, Banach M, Sahebkar A. Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study. Front Cardiovasc Med 2022;9:820260. [DOI: 10.3389/fcvm.2022.820260] [Reference Citation Analysis]
11 Chatterjee S, Vardhan B, Singh DK, Maitra A, Ojha UK. Should statins be considered for the management of mucormycosis in COVID-19? Diabetes Metab Syndr 2021;15:102162. [PMID: 34186353 DOI: 10.1016/j.dsx.2021.05.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]